The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel. There is no evidence that either of the two treatments was superior to the other in the prevention of recurrent stroke. (ClinicalTrials.gov number, NCT00153062.)
Authors: Ralph L. Sacco, Hans‐Christoph Diener, Salim Yusuf, Otto W. Witte, Stephanie Ôunpuu, William A Lawton, Yuko Palesch, Renée H. Martin, Gregory W. Albers, Philip M. Bath, Natan M. Bornstein, Bernard P.L. Chan, Christopher Chen, Luı́s Cunha, Björn Dahlöf, Jacques De Keyser, Geoffrey A. Donnan, Conrado J. Estol, Philip B. Gorelick, Vivian Gu, Karin Hermansson, Lutz Hilbrich, Markku Kaste, Chuanzhen Lü, Thomas Machnig, Prem Pais, Robin Roberts, Veronika Skvortsova, Philip Teal, Danilo Toni, Cam P. VanderMaelen, Thor Voigt, Michael A. Weber, Byung‐Woo Yoon
DOI: https://doi.org/10.1056/nejmoa0805002
Publish Year: 2008
